Company / Current Liabilities
Vivos Therapeutics, Inc. Current Liabilities History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$18.1M
FY2025
5-year range
$5.0M / $18.1M
FY2021-FY2025
Trend
+263.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities changed +263% YoY in FY2025, a notable deviation from the 5-year average annual change of +45%.
Based on SEC 10-K filings.
$18M in FY2025 with a 5-year CAGR of +18.2%.
Increased from $7M to $18M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +38.4%
- 5-Year CAGR
- +18.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +18.2%, indicating consistent growth.
- In FY2025, current liabilities increased 263.1% year-over-year.
- Lowest current liabilities in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.1M | +263.1% |
| FY2024 | $5.0M | -26.9% |
| FY2023 | $6.8M | +0.0% |
| FY2022 | $6.8M | -9.3% |
| FY2021 | $7.5M | -4.0% |
| FY2020 | $7.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026